Patents by Inventor Christa Mayer
Christa Mayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230242897Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: ApplicationFiled: April 11, 2023Publication date: August 3, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 11661593Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: GrantFiled: December 16, 2014Date of Patent: May 30, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Publication number: 20220275058Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.Type: ApplicationFiled: March 7, 2022Publication date: September 1, 2022Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
-
Patent number: 11299533Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.Type: GrantFiled: June 22, 2018Date of Patent: April 12, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
-
Publication number: 20220041693Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: ApplicationFiled: February 8, 2021Publication date: February 10, 2022Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Patent number: 10934340Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: GrantFiled: March 20, 2019Date of Patent: March 2, 2021Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20190382467Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: ApplicationFiled: March 20, 2019Publication date: December 19, 2019Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20190062403Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.Type: ApplicationFiled: June 22, 2018Publication date: February 28, 2019Applicants: Baxalta Incorporated, Baxalta GmbHInventors: Meinhard HASSLACHER, Martin FEICHTINGER, Philipp M. BÄRNTHALER, Christa MAYER, Birgit REIPERT, Mantas MALISAUSKAS, Julia ANZENGRUBER
-
Patent number: 9315560Abstract: The present invention provides methods for purifying Von Willebrand factor (VWF) for increased removal of non-lipid enveloped viruses.Type: GrantFiled: August 20, 2010Date of Patent: April 19, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20150104849Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: ApplicationFiled: December 16, 2014Publication date: April 16, 2015Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 8945895Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: GrantFiled: July 30, 2010Date of Patent: February 3, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 8388847Abstract: The invention relates generally to methods of concentrating mixtures including shear sensitive biopolymers, such as von Willebrand Factor. Conventional methods of concentrating biopolymers impart too much shear stress, which causes the degradation of shear sensitive biopolymers. The methods disclosed herein reduce the shear stress while maintaining a high rate of filtrate flux. Disclosed herein is a method for concentrating shear sensitive biopolymers including flowing a mixture with a shear sensitive biopolymer into a hollow fiber dialysis module to form a retentate having a shear sensitive biopolymer concentration that is greater than that of the mixture. Hollow fiber dialysis modules have high filtrate fluxes and low shear rates at low flow rates. This ensures a high product yield and minimal loss of shear sensitive biopolymers.Type: GrantFiled: August 27, 2009Date of Patent: March 5, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20120076779Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing a labile therapeutic protein composition at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of labile proteins at mildly acidic to neutral pH useful for parenteral administration.Type: ApplicationFiled: September 16, 2011Publication date: March 29, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Harald Arno Butterweck, Theresa Friederike Bauer, Lucia Hofbauer, Wolfgang Teschner, Oliver Zoechling, Hans-Peter Schwarz, Christa Mayer, Meinhard Hasslacher
-
Patent number: 8058411Abstract: The present invention relates to a method for producing a mature von Willebrand Factor (VWF) from von Willebrand Factor pro-peptide comprising the steps: immobilizing VWF pro-peptide on an ion exchange resin, incubating the immobilized VWF pro-peptide with furin to obtain immobilized mature VWF, and isolating mature VWF from the ion exchange resin by elution.Type: GrantFiled: May 16, 2008Date of Patent: November 15, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Wolfgang Mundt, Artur Mitterer, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20110092681Abstract: The present invention provides methods for purifying Von Willebrand factor (VWF) for increased removal of non-lipid enveloped viruses.Type: ApplicationFiled: August 20, 2010Publication date: April 21, 2011Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: ARTUR MITTERER, MEINHARD HASSLACHER, CHRISTA MAYER
-
Publication number: 20110081700Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: ApplicationFiled: July 30, 2010Publication date: April 7, 2011Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Publication number: 20100051550Abstract: The invention relates generally to methods of concentrating mixtures including shear sensitive biopolymers, such as von Willebrand Factor. Conventional methods of concentrating biopolymers impart too much shear stress, which causes the degradation of shear sensitive biopolymers. The methods disclosed herein reduce the shear stress while maintaining a high rate of filtrate flux. Disclosed herein is a method for concentrating shear sensitive biopolymers including flowing a mixture with a shear sensitive biopolymer into a hollow fiber dialysis module to form a retentate having a shear sensitive biopolymer concentration that is greater than that of the mixture. Hollow fiber dialysis modules have high filtrate fluxes and low shear rates at low flow rates. This ensures a high product yield and minimal loss of shear sensitive biopolymers.Type: ApplicationFiled: August 27, 2009Publication date: March 4, 2010Applicants: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC.Inventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20090029918Abstract: The present invention relates to a method for producing a mature von Willebrand Factor (VWF) from von Willebrand Factor pro-peptide comprising the steps: immobilizing VWF pro-peptide on an ion exchange resin, incubating the immobilized VWF pro-peptide with furin to obtain immobilized mature VWF, and isolating mature VWF from the ion exchange resin by elution.Type: ApplicationFiled: May 16, 2008Publication date: January 29, 2009Applicants: Baxter International Inc., Baxter Healthcare SAInventors: Wolfgang Mundt, Artur Mitterer, Meinhard Hasslacher, Christa Mayer